{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:39:57Z","timestamp":1782488397995,"version":"3.54.5"},"reference-count":49,"publisher":"BMJ","issue":"2","funder":[{"name":"European Union, European Social Fund"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2017,8,14]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:p>\n                  <jats:italic>Streptococcus pneumoniae<\/jats:italic> is the leading cause of the community-acquired pneumonia. The mortality rate of invasive pneumococcal infections is high. Immunocompromised patients suffering from autoimmune inflammatory rheumatic diseases (AIRD) have a high risk for acquiring these infections. Protection against infection can be improved with vaccination. After using polysaccharide vaccines (PPV-23), in July 2013, a 13-valent conjugate vaccine (PCV-13) was approved for adults. Due to its conjugate form, this vaccine is the recommended choice in pneumococcal vaccine-naive patients. PCV-13 is also recommended in patients previously receiving PPV-23. Vaccination in AIRD is very important and needs deliberate scheduling to coordinate with the immunosuppressive therapy. Here, based on international and national vaccine guidelines, we provide a current review of PPV-23 and PCV-13 vaccines for specialists following patients with AIRD.<\/jats:p>","DOI":"10.1136\/rmdopen-2017-000484","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T20:10:19Z","timestamp":1505506219000},"page":"e000484","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Pneumococcal vaccination in autoimmune rheumatic diseases"],"prefix":"10.1136","volume":"3","author":[{"given":"\u00c9va","family":"R\u00e1k\u00f3czi","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, University of Debrecen Faculty of Medicine, Ken\u00e9zy University Hospital, Debrecen, Hungary"},{"name":"Division of Rheumatology, Department of Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"2025090313532139000_3.2.e000484.1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"2025090313532139000_3.2.e000484.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.6.3854"},{"key":"2025090313532139000_3.2.e000484.3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-07"},{"key":"2025090313532139000_3.2.e000484.4","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.933077"},{"key":"2025090313532139000_3.2.e000484.5","unstructured":"Annual epidemiological report. Vaccine-preventable diseases \u2013 invasive bacterial diseases. 2014 www.ecdc.europa.eu."},{"key":"2025090313532139000_3.2.e000484.6","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"2025090313532139000_3.2.e000484.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204282"},{"key":"2025090313532139000_3.2.e000484.8","unstructured":"Butler J . Epidemiology of pneumococcal disease. In: Tuomanen E , Mitchell T , Morrison D , Spratt B , eds. The Pneumococcus. 10. Washington DC: American Society for Microbiology, \u00a02004:148\u201368."},{"key":"2025090313532139000_3.2.e000484.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22246"},{"key":"2025090313532139000_3.2.e000484.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057265"},{"key":"2025090313532139000_3.2.e000484.11","first-page":"1900","article-title":"Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study","volume":"25","author":"Hern\u00e1ndez-Cruz","year":"1998","journal-title":"J Rheumatol"},{"key":"2025090313532139000_3.2.e000484.12","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200109000-00002"},{"key":"2025090313532139000_3.2.e000484.13","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678919930"},{"key":"2025090313532139000_3.2.e000484.14","first-page":"62","article-title":"Evaluation of the mortality in systematic lupus erythematosus (SLE): analysis of 2021 patients","volume":"41","author":"Gharibdoost","year":"2003","journal-title":"Acta medica Iranica"},{"key":"2025090313532139000_3.2.e000484.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0441-9"},{"key":"2025090313532139000_3.2.e000484.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61204-6"},{"key":"2025090313532139000_3.2.e000484.17","doi-asserted-by":"publisher","DOI":"10.1086\/313608"},{"key":"2025090313532139000_3.2.e000484.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.002"},{"key":"2025090313532139000_3.2.e000484.19","doi-asserted-by":"publisher","DOI":"10.1086\/313609"},{"key":"2025090313532139000_3.2.e000484.20","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","author":"Centers for Disease C, Prevention, Advisory Committee on Immunization P","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090313532139000_3.2.e000484.21","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among chPreviously received PPV-23 in immunocompromised adult, when aged","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090313532139000_3.2.e000484.22","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.636348"},{"key":"2025090313532139000_3.2.e000484.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.031"},{"key":"2025090313532139000_3.2.e000484.24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000422.pub2"},{"key":"2025090313532139000_3.2.e000484.25","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090313532139000_3.2.e000484.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.16.2043"},{"key":"2025090313532139000_3.2.e000484.27","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12188"},{"key":"2025090313532139000_3.2.e000484.28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2494"},{"key":"2025090313532139000_3.2.e000484.29","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: Analysis of the 2014 WHO\/UNICEF Joint Reporting Form on immunization","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine"},{"key":"2025090313532139000_3.2.e000484.30","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper--2012","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"2025090313532139000_3.2.e000484.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.093"},{"key":"2025090313532139000_3.2.e000484.32","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000689"},{"key":"2025090313532139000_3.2.e000484.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114966","article-title":"Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report","volume":"9","author":"Pasiarski","year":"2014","journal-title":"PLoS One"},{"key":"2025090313532139000_3.2.e000484.34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13075-016-1207-7","article-title":"The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial","volume":"19","author":"Izumi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090313532139000_3.2.e000484.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei193"},{"key":"2025090313532139000_3.2.e000484.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204427"},{"key":"2025090313532139000_3.2.e000484.37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12891-016-1082-z","article-title":"Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept","volume":"17","author":"Alten","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090313532139000_3.2.e000484.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1856-5"},{"key":"2025090313532139000_3.2.e000484.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.30580"},{"key":"2025090313532139000_3.2.e000484.40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/03009742.2014.984754","article-title":"The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients","volume":"44","author":"Nagel","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2025090313532139000_3.2.e000484.41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jbspin.2015.10.017","article-title":"Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept","volume":"83","author":"R\u00e1k\u00f3czi","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090313532139000_3.2.e000484.42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"2025090313532139000_3.2.e000484.43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203316686406","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld\u2019s syndrome) - An update","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"},{"key":"2025090313532139000_3.2.e000484.44","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.vaccine.2015.09.027","article-title":"Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases","volume":"34","author":"Felicetti","year":"2016","journal-title":"Vaccine"},{"key":"2025090313532139000_3.2.e000484.45","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/rheumatology\/kex185","article-title":"Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study","volume":"56","author":"Jaeger","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313532139000_3.2.e000484.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"2025090313532139000_3.2.e000484.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.12.003"},{"key":"2025090313532139000_3.2.e000484.48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"2025090313532139000_3.2.e000484.49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","article-title":"Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis","volume":"80","author":"Lopez","year":"2017","journal-title":"J Autoimmun"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:53:30Z","timestamp":1756932810000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,14]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/rmdopen-2017-000484"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000484","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}